The different major therapy options used are: 33% first line patients were treated with dacarbazine, 20% with fotemustine, and 12% with a combination of dacarbazine+fotemustine; in Acalabrutinib in vivo second line, 51% of patients were treated with fotemustine, and 10% with dacarbazine; in third line, fotemustine was used for 40% of patients, while dacarbazine for 8% of patients. The mean age at the diagnosis was 55 years and male patients represented 62.9% of the sample. Among the 300 therapeutic treatments 42.8% showed some response to systemic therapy. Within each

line of therapy – that is net of double counting – response rate was lower (36.1% in the first line, 30.4% Selleck ATM Kinase Inhibitor in the second line and 34.1 in the third line). The total length of follow-up time was 17.5 months, with lower durations in the first line (9.9 months) in the second line (8.9 months) and in the third line

(4.9 months). Hospitalization Hospitalizations were Gilteritinib datasheet not particularly frequent, with less than 10% of all patients experiencing it. Hospitalization tended to be more frequent (12.4% vs 5.9%) for patients with any response to systemic therapy in comparison with those with no response (Table 3, Table 4 and Table 5). Hospitalization was the most expensive category of resource utilisation, both among those who experienced

hospitalization (mean total cost of € 25,540) and with reference to the generality of the sample (i.e. including Calpain patients with zero utilisation): € 2,481. Moreover, the mean cost per patient with any response to systemic therapy was higher than the mean cost per patient with no response (€ 4,524 vs € 882); the mean cost per patient in the first line of therapy (€ 2,634) was higher than the overall cost (€ 2,481), and much higher than the mean cost per patient in the second (€ 588) and third (€1.356) line of therapy. Table 3 Summary statistics for hospitalizations for patients receiving systemic therapy and/or supportive care     Overall First-line therapy Second-line therapy Third-line therapy Supportive care N   215 147 112 41 24 Patients with any hospitalization N 21 11 7 4 4   % 9,8% 7,5% 6,3% 9,8% 16,7% Total length of hospitalization (days) Mean 34,3 47,5 12,7 18,8 8,2   95%CI 0-73,7 0-126,6 6,6-18,8 0-38,9 1,1-15,4 Length of hospitalization (days/month(1)) Mean 1,9 11,6 6,1 7,5 19,8   95%CI 0,6-3,2 0-30,8 0-15,3 0-27,4 0-74,2 Total hospitalization cost per hospitalized patient (€ 2009) Mean 25.400 35.200 9.400 13.900 6.100   95% CI 0-54.500 0-93.